Beyond Levodopa: A Whole-System Approach to Supporting Parkinson’s Disease

Parkinson's disease (PD) affects an estimated 11.7 million people worldwide, and it isn't evenly distributed. North America's prevalence runs around 1,600 cases per 100,000 people, compared to roughly 646 per 100,000 in Asia, a gap researchers haven't been able to fully explain by age structure alone. The pattern sharpens further inside the U.S. itself: Nebraska and Kansas post the highest state-level diagnosis rates in the country, even after adjusting for age, sex, and comorbidities, and the Rust Belt, Southern California, Southeastern Texas, and Florida all show elevated incidence as well. That geographic footprint has researchers looking closely at environmental exposures, such as pesticides and industrial chemicals, as possible contributors. To be clear, this is a documented association, not a proven mechanism. Layered onto that uncertainty is a tradeoff baked into standard treatment itself: levodopa, still the backbone of Parkinson's care, can quietly raise homocysteine with every dose. That's not a reason to avoid levodopa, but together with the challenges faced by those with Parkinson's even with treatment are reason to build a fuller support plan.

Acupuncture

Acupuncture for Motor Symptoms

The most useful data point here comes from a 2021 meta-analysis pooling 66 randomized trials of acupuncture-related therapies added to conventional Parkinson's medication. Compared to medication alone, adding acupuncture produced a meaningful drop in motor symptom scores on the Unified Parkinson's Disease Rating Scale (UPDRS-III), along with improvements in total UPDRS score and activities of daily living.

A more recent 2023 dose-response analysis of 16 trials found a similar effect size on motor scores and, notably, identified that the benefit wasn't simply "more is better." They divided the approaches into two groups, those that incorporated acupuncture less than 3 times/week and those that incorporated acupuncture more than 3 times/week. From there, there appears be a therapeutic window. The impact climbs with more acupuncture. As total visits move beyond 60 visits, you see less impact. Additional sessions beyond this point stopped adding value and could even plateau or reverse, which lines up with something acupuncturists have long suspected clinically: the body can develop a degree of tolerance to excessive stimulation. More visits a week did show more obvious impact, but again, you still hit a point where impact is less, just faster.

More research is needed to explore this, but clinically, I've found regular weekly treatments to be most beneficial. I don't tend to recommend more than that unless it's for a specific purpose. Moreover, I only venture beyond once a week for short-term care plans for rehabilitation purposes, such as stroke recovery.

Acupuncture also shows up in the non-motor symptom data, which matters because non-motor symptoms — sleep disruption, depression, cognitive fog — are often what patients say erodes quality of life the most. A 2022 meta-analysis of 27 RCTs found acupuncture combined with medication improved insomnia, depression, cognition, and quality-of-life scores relative to medication or sham treatment alone, though the effect on constipation didn't reach significance.

The most recent decade-spanning systematic review, covering 38 RCTs and nearly 2,800 participants, reached a similarly positive conclusion on the combined approach — acupuncture alongside Western medicine outperformed Western medicine alone.

Important caveat you'll see a lot: More research is needed.

I can hear my students giggling. This is always the conclusion of pretty much all studies, but acupuncture presents real problems where consistency is concerned. For one, the treatments are traditionally personalized. Traditional research likes consistent protocols. Clinically, I find personalization is best. There are overlaps of course, but the variance in acupuncture as an intervention is a real challenge to research without rethinking how we approach our research methodology. The variance is also a real strength of Chinese medicine.

Inflammation

The Homocysteine Problem

Levodopa itself drives homocysteine up. What the heck is homocysteine. It is a compound that is converted to usable cystein in a methylation cycle that helps you to create your body's main antioxidant (glutathione) while creating a number of important by-products along the way.

The mechanism around levodopa is a direct methylation story. Levodopa is broken down peripherally by the enzyme COMT (catechol-O-methyltransferase), and that reaction requires a methyl group donated by SAMe (S-adenosylmethionine, the same universal methyl donor your body uses for dozens of other jobs, including neurotransmitter synthesis. Every time COMT methylates a dose of levodopa, it generates S-adenosylhomocysteine as a byproduct, which then hydrolyzes into homocysteine. Multiple studies have confirmed this isn't theoretical: plasma homocysteine rises measurably after both acute and chronic levodopa dosing, and the effect is large enough that levodopa-treated PD patients run meaningfully higher homocysteine than dopamine-agonist-only patients or healthy controls.

Why this matters clinically: elevated homocysteine in levodopa-treated PD patients has been associated with roughly double the prevalence of coronary artery disease compared to those with normal levels, on top of the general cardiovascular and cognitive risks homocysteine carries in any population. Adding a COMT inhibitor like entacapone was proposed as a fix, since it should theoretically reduce the methylation burden — but the clinical data on whether it actually normalizes homocysteine has been inconsistent, with some trials showing a meaningful reduction and others showing no significant difference.

"I don't methylate well." Where does MTHFR fit?

This is where the genetics conversation gets nuanced. MTHFR variants, particularly C677T, can reduce the efficiency of folate metabolism and influence the methylation cycle. Meanwhile, levodopa metabolism through COMT increases demand for methyl donors and can raise homocysteine levels. For patients with reduced methylation capacity, this raises an interesting question: could individual genetic differences influence how well someone tolerates the metabolic demands of long-term levodopa therapy? This is one plausible explanation for why some patients develop higher homocysteine levels than others on similar medication regimens.

The genetic association data on MTHFR and PD risk itself is genuinely mixed. A meta-analysis of 19 studies covering nearly 2,750 cases found no overall association between the C677T variant and PD risk, though it did find an association in Caucasian subgroups specifically. What's more consistently supported is a narrower, more clinically useful finding: the C677T polymorphism appears to influence age of onset in PD patients who already have the disease, which is a different and more actionable question than "does MTHFR cause PD?" It doesn't. Whether it modifies the metabolic terrain patients are managing once they're on levodopa is the more defensible clinical question, and it's consistent with the broader methylation mechanism above. So what do you do for MTHFR mutation? Common supplements are N-Acetyl-Cysteine to support glutathione production and pre-methylated B-vitamins. (i.e. Methyl-folate vs Folic Acid)

Protecting Neurons: Emerging Research

Herbs that protect dopaminergic neurons and may target Lewy bodies

Tian Ma (Gastrodia elata / Tianma).

This is one of the better-studied TCM herbs for PD specifically. A 2022 review found that Tianma and its bioactive components (gastrodin and 4-hydroxybenzyl alcohol) reduce dopaminergic neuron death, α-synuclein accumulation, and neuroinflammation across multiple PD models. Separately, in an MPTP mouse model (a standard way researchers chemically induce Parkinson's-like dopaminergic neuron loss) Gastrodia elata extract prevented MPTP-induced dopaminergic death in the substantia nigra. A more recent mechanistic study went further, showing Gastrodia elata protects dopaminergic neurons in a genetic (LRRK2-G2019S) fly and mouse model of PD by activating the Nrf2 antioxidant pathway in glial cells, not just in the neurons themselves — suggesting the protective effect works partly through supporting the neurons' surrounding support cells. Tian Ma is a classic herb for "wind," how tremors are discussed in Chinese medicine, and the value is founded. The research around mechanisms and potential ability to tackle α-synuclein accumulation is early.

San Qi (Panax notoginseng)

This is an herb we traditionally use for regulation of blood— transforming stasis, moving blood where it isn't and regulating how it moved. It's studied a good deal for stroke for obvious reasons, but while I was in China we would discuss it in a sense of renewal. So in that context, what role might it play with α-synuclein and Lewy bodies? San Qi's saponins include panaxatriol saponins, which provided neuroprotection against dopaminergic neuron loss and behavioral impairment in an MPTP mouse model of PD, operating through increased Trx-1 expression and inhibition of mitochondrial-mediated apoptosis.

But the more striking finding is specific to ginsenoside Rb1 — a saponin San Qi shares with regular ginseng — which was shown in a 2015 Neurobiology of Disease study to be a potent inhibitor of alpha-synuclein fibrillation and toxicity, and to actively disaggregate preformed alpha-synuclein fibrils. That's directly on-target for the Lewy body problem: alpha-synuclein misfolding and aggregation into fibrils is the molecular event that becomes Lewy bodies, and Rb1 was the only one of three tested ginsenosides (Rb1, Rg1, Rg3) that had this effect. It's an in vitro/cell-culture finding, not a human trial, so it's mechanistic promise rather than clinical proof — but it's a much more specific hit than general "neuroprotection" language, and it's exactly the kind of anti-aggregation activity you'd want if the goal is targeting Lewy body formation itself rather than just protecting neurons from downstream damage.

Green tea / EGCG (epigallocatechin gallate)

This one has epidemiological backing in humans, not just animal models. Habitual tea consumption, particularly of catechin- and EGCG-rich green tea, is inversely correlated with PD onset across multiple longitudinal studies, and mechanistically, EGCG has been shown to prevent loss of tyrosine hydroxylase-positive cells in the substantia nigra — tyrosine hydroxylase being the rate-limiting enzyme in dopamine synthesis, so protecting those specific cells is directly protecting dopamine-producing capacity. One caveat worth keeping in the post: EGCG's effects appear to be dose-dependent, promoting cell survival at low-to-moderate doses but potentially promoting cell death at high doses in some studies — so "more is better" doesn't hold here, which is a useful nuance for readers tempted to supplement aggressively.

Foods Worth Looking at

• Blueberries — pooled analysis of ~150,000 people found lower PD risk with highest anthocyanin/berry intake (RR 0.76–0.77); extract restored mitochondrial function in dopaminergic cells exposed to rotenone.

• Coffee/caffeine — meta-analysis of 13 studies: caffeine lowered PD risk in healthy people (HR 0.80) and slowed motor progression in existing PD patients (HR 0.83) — one of the few foods with evidence on both prevention and progression. Mechanism: adenosine A2A receptor antagonism, the same target as the approved PD drug istradefylline.

• Turmeric/curcumin — binds directly to alpha-synuclein, preventing aggregation; separately implicated in autophagy-mediated alpha-synuclein clearance — a second, distinct anti-Lewy body mechanism alongside San Qi's Rb1.

• Cinnamon — prevented dopaminergic death and motor deficits in MPTP mice via Parkin/DJ-1 upregulation; also shown to affect alpha-synuclein oligomerization. Animal-model evidence only, no human PD trials yet.

• Lion's Mane (Hericium erinaceus) — improved oxidative stress and dopaminergic lesions in an animal PD modelvia NGF induction. Thinnest evidence base of the group — most human data is on cognition/MCI, not PD specifically.

• Fava beans (Vicia faba) — different category: contains actual levodopa (~170 mg/100g in some genotypes), and a 2023 crossover trial found comparable effect to standard Levodopa-C. Flag prominently: this isn't a supportive food, it's an uncontrolled dose of the same drug patients are already titrating — needs a neurologist conversation, not a dietary tweak, and carries a separate G6PD/favism risk.

Chinese Herbs Worth Looking at | Inflammation Focus

The following herbs have intersections with our key inflammatory mediators identified in other posts.

• Astragalus (Huang Qi) has the deepest and most consistent NF-κB evidence of the group. Astragaloside IV inhibits NF-κB-mediated inflammatory gene expression and attenuates diabetic nephropathy through this pathway, while astragalus polysaccharides suppress TNF-α and IL-1β by blocking NF-κB activation in LPS-stimulated macrophages — reproduced across TLR4/NF-κB, p38 MAPK, and AMPK signaling in multiple models.

• Huang Qin (Scutellaria baicalensis) anchors this space with baicalin, which reduces inflammation via the SOCS1/NF-κB/STAT3 axis and underlies classic formulas like Huang-Lian-Jie-Du-Decoction used for sepsis-adjacent inflammatory states.

• Huang Lian (Coptis chinensis) / berberine moves past cell culture into real clinical application. It reduces NF-κB expression and inflammatory response in the colon in ulcerative colitis, and its isoquinoline alkaloids show a documented "cytokine storm-calming" property — relevant for acute-flare framing, not just chronic low-grade inflammation. It's also the standout for gut-microbiome-mediated anti-inflammatory action, distinct from most botanicals here.

• Bai Zhu (Atractylodes macrocephala) has the cleanest dose-response mechanistic data: three isolated compounds suppressed NF-κB nuclear translocation and MAPK (p38/JNK/ERK1/2) phosphorylation, reducing iNOS, COX-2, and pro-inflammatory cytokines in a concentration-dependent manner. It's also strong for gut-barrier work specifically — polysaccharides regulate intestinal tight-junction proteins (occludin, claudins, ZO-1).

• Bai Zhi (Angelica dahurica) coumarins (imperatorin, isoimperatorin, osthole) lower TNF-α, IL-1β, IL-6, iNOS, and COX-2 across pain and inflammation models, with a documented airway application: reduced airway eosinophilia and cytokine levels in an ovalbumin-induced asthma model.

• Gan Cao (licorice) has genuine clinical-trial-adjacent evidence. An aqueous extract is a constituent of ASHMI (Anti-Asthma Herbal Medicine Intervention), which showed therapeutic effects in a controlled clinical trial of moderate-to-severe asthmatics, and its flavonoids inhibit eotaxin-1 secretion — the chemokine that recruits eosinophils in allergic airway disease. Mechanistically, licorice extract prevents NF-κB and AP-1 activation and reduces TNF-α, IL-6, and IL-1β in macrophage models.

  • Safety Flag at HIGH Doses: glycyrrhizin (the major triterpenoid) is well known to cause pseudoaldosteronism — sodium retention, potassium loss, and hypertension.

• Jin Yin Hua (Lonicera japonica / honeysuckle) — chlorogenic acid, its primary marker compound, downregulates IL-6, TNF-α, IFN-γ, and MCP-1 in infection models, and the herb anchors several clinically used injectable formulas for respiratory inflammation (Re Du Ning, Tan Re Qing, Xi Yan Ping) in Chinese hospital practice — though it's worth noting most of that clinical use is domestic to China and hasn't gone through the same trial infrastructure as ASHMI.

• Xanthium (Cang Er Zi) — xanthatin decreases NO, ROS, and inflammatory cytokines by down-regulating NF-κB, MAPK, and STAT signaling, and separately covalently binds JAK and IKK kinases to inhibit STAT3/NF-κB — a more targeted mechanism than most herbs here.

  • Safety Flag: raw or excess Xanthium fruit is documented as hepatotoxic and neurotoxic — case reports describe muscle spasm and hepatic injury from Cang Er Zi Wan. This is a processed-and-dosed-correctly herb, not a casual addition.

Putting it Together

Everyone is different and merit a personalized treatment plan. First-line treatment is levodopa. Nothing currently available replaces it for motor control, but that doesn't mean you can't take a comprehensive approach. Work closely with your neurologist on any changes you make.

• Genetic Testing Know where you're starting! It could be interesting to see if you have the mutation for LRRK2 or GBA1, but it doesn't necessarily change much. Labcorps can be an option if you want to go that direction. However(!), it's worth finding out where you stand genetically with inflammation. I've come to like 3x4 Genetics. It's super easy to use and it will check for a number of inflammatory pathways.

• Nutritional Approaches for Inflammation This can go multiple ways. With your genetic information, you may find you need specific support like DAO or methylation support. You'll also likely want to lower inflammation by tackling food sensitivities and allergies while incorporating more colorful and sulfur rich vegetables will help you tackle key inflammatory pathways. Herbs worth looking at if they match your constitution. Meaning, some of these are used for digestion and energy whereas some are used for infection. They may not make sense for your overall presentation.

  • Astragalus (Huang Qi)

  • Huang Qin (Scutellaria baicalensis)

  • Huang Lian (Coptis chinensis) / berberine

  • Bai Zhu (Atractylodes macrocephala)

  • Bai Zhi (Angelica dahurica)

  • Gan Cao (Glycyrrhiza / licorice)

  • Jin Yin Hua (Lonicera japonica / honeysuckle)

  • Xanthium (Cang Er Zi)
    

• Nutritional Approaches for Neuronal Support Topline options to consider

  • Iron + Vitamin C for Tyrosine Hydroxylase

  • Green Tea

  • Gastrodia

  • Panax Ginseng

  • Panax Notoginseng

  • Methylation support as a standing consideration for anyone on chronic levodopa, independent of known MTHFR status, given that the homocysteine rise is a documented pharmacological effect of the drug itself, not a rare idiosyncrasy.
    

• Acupuncture Meta-analyses of acupuncture added to standard Parkinson's medication show measurable improvement in motor scores (UPDRS-III) and several non-motor domains (sleep, mood, cognition), and it does appear to be dose-dependent intervention. Clinically, I prefer regular weekly treatments, but there's rate of diminished return beyond that. The data indicates this is likely beyond 60 treatments. Any more than a handful of visits beyond weekly likely diminish efficacy.

• Deep Brain Stimulator (DBS) We haven't discussed this yet, and it's beyond the scope of my expertise. I can say that in my experience, DBS implantation can be game-changing. If you are a candidate, it's worth your consideration.

---

Dr. Diane Stanley is a doctor of acupuncture and Chinese medicine. Blog content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making changes to your health routine.

---

References

1. Global and Regional Patterns of Parkinson's Disease: Temporal Trends, Inequality Gaps, and Projections to 2040. medRxiv (2025). https://www.medrxiv.org/content/10.1101/2025.10.22.25338533.full.pdf

2. Temporal Trends in Parkinson's Disease Related Mortality from 1999–2020: A National Analysis. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739699/

3. Epic Research. Parkinson's Diagnoses Highest in Nebraska and Kansas (2025). https://www.epicresearch.org/articles/parkinsons-diagnoses-highest-in-nebraska-and-kansas/

4. Parkinson's Foundation. Statistics. https://www.parkinson.org/understanding-parkinsons/statistics

5. Lamberti, P., Zoccolella, S., Iliceto, G., et al. (2004). Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Movement Disorders, 20(1), 69–72. https://doi.org/10.1002/mds.20261

6. Luo, J. J., Zhang, L., & Dun, N. J. (2022). Homocysteine and Dementia in Parkinson Disease. In Parkinson's Disease. IntechOpen. https://doi.org/10.5772/intechopen.100192

7. Koçer, B., Güven, H., & Çomoğlu, S. S. (2016). Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective? BioMed Research International. https://doi.org/10.1155/2016/7563705

8. The MTHFR C677T polymorphism modifies age at onset in Parkinson's disease. Journal of the Neurological Sciences. PMID: 24052451.

9. Wu, Y. L., Ding, X. X., Sun, Y. H., et al. (2013). Methylenetetrahydrofolate reductase (MTHFR) C677T/A1298C polymorphisms and susceptibility to Parkinson's disease: a meta-analysis. Journal of the Neurological Sciences, 335(1-2), 14–21.

10. Wen, X., Li, K., Wen, H., et al. (2021). Acupuncture-Related Therapies for Parkinson's Disease: A Meta-Analysis and Qualitative Review. Frontiers in Aging Neuroscience, 13. https://doi.org/10.3389/fnagi.2021.676827

11. Lei, S., Fan, J., Liu, X., et al. (2023). Qualitative and quantitative meta-analysis of acupuncture effects on the motor function of Parkinson's disease patients. Frontiers in Neuroscience, 17. https://doi.org/10.3389/fnins.2023.1125626

12. Li, Q., Wu, C., Wang, X., et al. (2022). Effect of acupuncture for non-motor symptoms in patients with Parkinson's disease. Frontiers in Aging Neuroscience, 14. https://doi.org/10.3389/fnagi.2022.995850

13. Kim, Y.-D., Lim, Y., Ahn, S., et al. (2024). Efficacy of Acupuncture for Parkinson's Disease over the Last Decade. Journal of Acupuncture Research, 41(1), 29–52. https://doi.org/10.13045/jar.2024.00024

14. Lu, C., Qu, S., Zhong, Z., et al. (2022). The effects of bioactive components from the rhizome of Gastrodia elata blume (Tianma) on the characteristics of Parkinson's disease. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.963327

15. Bae, C.-H., Kim, H.-Y., Lee, H., et al. (2022). Proteomic Analysis for Neuroprotective Effect of Gastrodia elata Blume in the Substantia Nigra of Mice. Korean Journal of Acupuncture, 39(4), 142–151. https://doi.org/10.14406/acu.2022.029

16. Lin, Y.-E., Lin, C.-H., Ho, E.-P., et al. (2021). Glial Nrf2 signaling mediates the neuroprotection exerted by Gastrodia elata Blume in Lrrk2-G2019S Parkinson's disease. eLife, 10. https://doi.org/10.7554/elife.73753

17. Ong, W.-Y. (2015). Protective effects of ginseng on neurological disorders. Frontiers in Aging Neuroscience, 7. https://doi.org/10.3389/fnagi.2015.00129

18. Ardah, M. T., Paleologou, K. E., Lv, G., et al. (2015). Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils. Neurobiology of Disease, 74, 89–101. https://doi.org/10.1016/j.nbd.2014.11.007

19. Kim, T. Y., Leem, E., Lee, J. M., et al. (2020). Control of Reactive Oxygen Species for the Prevention of Parkinson's Disease: The Possible Application of Flavonoids. Antioxidants, 9(7), 583. https://doi.org/10.3390/antiox9070583

20. Aboulwafa, M. M., Youssef, F. S., Gad, H. A., et al. (2019). A Comprehensive Insight on the Health Benefits and Phytoconstituents of Camellia sinensis. Antioxidants, 8(10), 455. https://doi.org/10.3390/antiox8100455

21. Kalt, W., Cassidy, A., Howard, L. R., et al. (2020). Recent Research on the Health Benefits of Blueberries and Their Anthocyanins. Advances in Nutrition, 11(2), 224–236. https://doi.org/10.1093/advances/nmz065

22. Zaa, C. A., Marcelo, Á., An, Z., et al. (2023). Anthocyanins: Molecular Aspects on Their Neuroprotective Activity. Biomolecules, 13(11), 1598. https://doi.org/10.3390/biom13111598

23. Hong, C.-T., Chan, L., & Bai, C.-H. (2020). The Effect of Caffeine on the Risk and Progression of Parkinson's Disease: A Meta-Analysis. Nutrients, 12(6), 1860. https://doi.org/10.3390/nu12061860

24. Neuroprotective Activities of Curcumin in Parkinson's Disease: A Review of the Literature. International Journal of Molecular Sciences, 22(20), 11248 (2021). https://doi.org/10.3390/ijms222011248

25. Biochemistry, Safety, Pharmacological Activities, and Clinical Applications of Turmeric. Evidence-Based Complementary and Alternative Medicine (2020). https://doi.org/10.1155/2020/7656919

26. Angelopoulou, E., Paudel, Y. N., Piperi, C., et al. (2021). Neuroprotective potential of cinnamon and its metabolites in Parkinson's disease. Journal of Biochemical and Molecular Toxicology, 35(4). https://doi.org/10.1002/jbt.22720

27. Spelman, K., Sutherland, E., & Bagade, A. (2017). Neurological Activity of Lion's Mane (Hericium erinaceus). Journal of Restorative Medicine, 6(1), 19–26. https://doi.org/10.14200/jrm.2017.6.0108

28. Nikkhah, K., Shoeibi, A., Rezaeitalab, F., et al. (2023). Efficacy and safety of Vicia faba L. extract compared with levodopa in management of Parkinson's disease. International Journal of Ayurvedic Medicine, 14(3), 794–800. https://doi.org/10.47552/ijam.v14i3.3481

29. Renna, M., De Cillis, F., Leoni, B., et al. (2020). From by-Product to Unconventional Vegetable: Preliminary Evaluation of Fresh Fava Hulls. Foods, 9(2), 159. https://doi.org/10.3390/foods9020159

30. Fu, J., Wang, Z., Huang, L., et al. (2014). Review of the Botanical Characteristics, Phytochemistry, and Pharmacology of Astragalus membranaceus. Phytotherapy Research, 28(9), 1275–1283.

31. Li, X., Qu, L., Dong, Y., et al. (2014). A Review of Recent Research Progress on the Astragalus Genus. Molecules, 19(11), 18850–18880. https://doi.org/10.3390/molecules191118850

32. Zheng, Y., Ren, W., Zhang, L., et al. (2020). A Review of the Pharmacological Action of Astragalus Polysaccharide. Frontiers in Pharmacology, 11. https://doi.org/10.3389/fphar.2020.00349

33. Baicalin reduces inflammation to inhibit lung cancer via targeting SOCS1/NF-κB/STAT3 axis. Heliyon (2024). https://doi.org/10.1016/j.heliyon.2024.e29361

34. Huang Lian for ulcerative colitis. Medicine, 99(38) (2020). https://doi.org/10.1097/md.0000000000022457

35. Cytokine storm-calming property of the isoquinoline alkaloids in Coptis chinensis Franch. Frontiers in Pharmacology(2022). https://doi.org/10.3389/fphar.2022.973587

36. Jeong, D., Dong, G.-Z., Lee, H. J., et al. (2019). Anti-Inflammatory Compounds from Atractylodes macrocephala. Molecules, 24(10), 1859. https://doi.org/10.3390/molecules24101859

37. Liu, C., Wang, S., Xiang, Z., et al. (2022). The chemistry and efficacy benefits of polysaccharides from Atractylodes macrocephala Koidz. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.952061

38. Li, X., Xu, H., Li, Y., et al. (2025). Research Progress of Coumarins in the Genus Angelica. Chemistry & Biodiversity, 22(12). https://doi.org/10.1002/cbdv.202500751

39. Batiha, G. E.-S., Shaheen, H. M., Elhawary, E. A., et al. (2022). Phytochemical Constituents, Folk Medicinal Uses, and Biological Activities of Genus Angelica. Molecules, 28(1), 267. https://doi.org/10.3390/molecules28010267

40. Bolleddula, J., Doddaga, S., Wang, R., et al. (2009). Licorice Flavonoids Inhibit Eotaxin-1 Secretion by Human Fetal Lung Fibroblasts in Vitro. Journal of Agricultural and Food Chemistry, 57(3), 820–825. https://doi.org/10.1021/jf802601j

41. Cho, H. J., Lim, S. S., & Kim, J.-S. (2009). The anti-inflammatory effects of Glycyrrhiza uralensis licorice extract. The FASEB Journal, 23(S1). https://doi.org/10.1096/fasebj.23.1_supplement.910.5

42. Wang, M., Tao, L., & Xu, H.-X. (2016). Chinese herbal medicines as a source of molecules with anti-enterovirus 71 activity. Chinese Medicine, 11(1). https://doi.org/10.1186/s13020-016-0074-0

43. Zhang, J., Zhao, R., Jin, L., et al. (2022). Xanthanolides in Xanthium L.: Structures, Synthesis and Bioactivity. Molecules, 27(23), 8136. https://doi.org/10.3390/molecules27238136

44. West, P. L., McKeown, N. J., & Hendrickson, R. G. (2010). Muscle spasm associated with therapeutic use of Cang Er Zi Wan. Clinical Toxicology, 48(4), 380–384. https://doi.org/10.3109/15563651003610161